Parietaria-specific Immunoglobulin E (Parietaria-specific IgE)

Parietaria-specific Immunoglobulin E (IgE) is a specialized antibody isotype that mediates allergic reactions to pollen from plants in the Parietaria genus, most notably Parietaria judaica and Parietaria officinalis (D'Amato et al., 2007, Allergy). These antibodies are produced by B cells following sensitization and bind with high affinity to FcεRI receptors on mast cells and basophils. Upon re-exposure to Parietaria allergens, such as the major allergens Par j 1 and Par j 2, the IgE molecules cross-link, triggering the degranulation of these effector cells and the release of inflammatory mediators like histamine (WHO/IUIS Allergen Nomenclature). This cascade results in the symptoms of seasonal allergic rhinitis and asthma, often referred to as "pellitory-of-the-wall" allergy. Therapeutic intervention typically involves the use of anti-IgE monoclonal antibodies like Omalizumab, which bind to the Fc region of circulating IgE to prevent its interaction with receptors (FDA Label, Xolair). Additionally, allergen-specific immunotherapy (AIT) is employed to reduce the levels of specific IgE or increase competing IgG4 antibodies, thereby inducing long-term clinical tolerance to the pollen (Zuberbier et al., 2021, Allergy).

Other names

Pellitory-specific IgEAnti-Parietaria IgEParietaria pollen-specific IgEsIgE to Parietaria

Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils (FDA Label, Xolair). Allergen-specific immunotherapy (AIT) works by inducing peripheral T-cell tolerance and promoting the production of allergen-specific IgG4 antibodies that compete with IgE for allergen binding (Zuberbier et al., 2021, Allergy).